These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 31136052)
1. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Marcellin P; Wong DK; Sievert W; Buggisch P; Petersen J; Flisiak R; Manns M; Kaita K; Krastev Z; Lee SS; Cathcart AL; Crans G; Op den Brouw M; Jump B; Gaggar A; Flaherty J; Buti M Liver Int; 2019 Oct; 39(10):1868-1875. PubMed ID: 31136052 [TBL] [Abstract][Full Text] [Related]
2. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Buti M; Tsai N; Petersen J; Flisiak R; Gurel S; Krastev Z; Aguilar Schall R; Flaherty JF; Martins EB; Charuworn P; Kitrinos KM; Subramanian GM; Gane E; Marcellin P Dig Dis Sci; 2015 May; 60(5):1457-64. PubMed ID: 25532501 [TBL] [Abstract][Full Text] [Related]
3. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126 [TBL] [Abstract][Full Text] [Related]
4. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946 [TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350 [TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. Hou JL; Gao ZL; Xie Q; Zhang JM; Sheng JF; Cheng J; Chen CW; Mao Q; Zhao W; Ren H; Tan DM; Niu JQ; Chen SJ; Pan C; Tang H; Wang H; Mao YM; Jia JD; Ning Q; Xu M; Wu SM; Li J; Zhang XX; Ji Y; Dong J; Li J J Viral Hepat; 2015 Feb; 22(2):85-93. PubMed ID: 25243325 [TBL] [Abstract][Full Text] [Related]
8. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497 [TBL] [Abstract][Full Text] [Related]
9. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545 [TBL] [Abstract][Full Text] [Related]
10. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704 [TBL] [Abstract][Full Text] [Related]
11. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735 [TBL] [Abstract][Full Text] [Related]
12. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. Pan CQ; Chan S; Trinh H; Yao A; Bae H; Lou L World J Gastroenterol; 2015 May; 21(18):5524-31. PubMed ID: 25987775 [TBL] [Abstract][Full Text] [Related]
13. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P; Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092 [TBL] [Abstract][Full Text] [Related]
14. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J; J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139 [TBL] [Abstract][Full Text] [Related]
15. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. Ahn SS; Chon YE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY Clin Mol Hepatol; 2014 Sep; 20(3):261-6. PubMed ID: 25320729 [TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833 [TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Liang X; Gao Z; Xie Q; Zhang J; Sheng J; Cheng J; Chen C; Mao Q; Zhao W; Ren H; Tan D; Niu J; Chen S; Pan C; Tang H; Wang H; Mao Y; Jia J; Ning Q; Xu M; Wu S; Li J; Zhang X; Zhang W; Xiong C; Hou J Hepatol Int; 2019 May; 13(3):260-269. PubMed ID: 30977033 [TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Liaw YF; Sheen IS; Lee CM; Akarca US; Papatheodoridis GV; Suet-Hing Wong F; Chang TT; Horban A; Wang C; Kwan P; Buti M; Prieto M; Berg T; Kitrinos K; Peschell K; Mondou E; Frederick D; Rousseau F; Schiff ER Hepatology; 2011 Jan; 53(1):62-72. PubMed ID: 21254162 [TBL] [Abstract][Full Text] [Related]